Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
24.40
-0.46 (-1.85%)
Streaming Delayed Price
Updated: 12:32 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
December 14, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
December 08, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
November 29, 2023
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.
Via
Benzinga
Topics
ETFs
Is Beam Therapeutics Stock a Buy Now?
November 18, 2023
It has plenty of money, but it'll be facing plenty of competition, too.
Via
The Motley Fool
Beam Therapeutics: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
The 3 Best Gene Editing Stocks on the Frontier of Medicine
November 20, 2023
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.
Via
InvestorPlace
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
November 14, 2023
You might not get a better chance to invest in these disruptive companies.
Via
The Motley Fool
Why Edible Garden Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session
November 13, 2023
Edible Garden AG Incorporated (NASDAQ: EDBL) shares fell on Monday following third-quarter results.
Via
Benzinga
Cathie Wood Loves This Beaten-Down Stock. But Is It in Trouble?
October 25, 2023
Beam Therapeutics' pipeline will look slimmer going forward.
Via
The Motley Fool
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
November 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
November 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners
November 06, 2023
Roku vaulted 50% to become Ark Innovation's top holding.
Via
Investor's Business Daily
2 Magnificent Growth Stocks That Might Be Badly Mispriced Right Now
November 05, 2023
These two beaten-down growth stocks could be brilliant buys for risk-tolerant investors.
Via
The Motley Fool
Inside Cathie Wood’s Portfolio: 3 Stocks She Is Betting Millions On
November 01, 2023
Are you looking to invest in disrupting stocks like Cathie Woods? Here are three stocks Cathie Wood is betting millions on.
Via
InvestorPlace
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
October 31, 2023
Lilly is putting its money where its mouth is with its purchase of cutting-edge medical technology.
Via
The Motley Fool
Verve Stock Soars On $250 Million Eli Lilly Deal
October 31, 2023
Eli Lilly now owns the opt-in rights to three more of Verve's cardiovascular drugs.
Via
Investor's Business Daily
Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday
October 31, 2023
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 31, 2023
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
After Cutting 20% of Its Staff, Is Beam Therapeutics Still a Buy?
October 31, 2023
Some of the strategic shifts proposed by management are for the better.
Via
The Motley Fool
Why Beam Therapeutics Stock Is Getting Bought Today
October 31, 2023
Beam Therapeutics Inc (NASDAQ: BEAM) shares are trading higher Tuesday after Eli Lilly And Co (NYSE: LLY) agreed to acquire certain rights under Beam's
Via
Benzinga
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
October 31, 2023
Beam to Receive $250 Million in Combined Upfront Payment and Equity Investment, Expected to Extend Beam’s Cash Runway to the Second Half of 2026
From
Beam Therapeutics
Via
GlobeNewswire
Cathie Wood's Ark Invest Scoops Up More Than $3M Worth Of SoFi Technologies Shares Amid Q3 Earnings Beat From Online Lender
October 30, 2023
Via
Benzinga
Topics
Earnings
Exposures
Financial
5 Reasons Beam Therapeutics Remains a Risky Stock
October 30, 2023
Shares of the gene-editing biotech might not have hit rock bottom yet.
Via
The Motley Fool
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
October 25, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Textainer Group, Roivant Sciences And Other Big Stocks Moving Higher In Monday's Pre-Market Session
October 23, 2023
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Beam Therapeutics Stock: Bear vs. Bull
October 21, 2023
This biotech has a few factors in its corner, but it also faces a difficult path.
Via
The Motley Fool
Investors Unpack Home Sales Data Ahead Of Fed Speech
October 19, 2023
Stocks are lower across the board, as investors unpack this morning's jobs and manufacturing data and await commentary from Federal Reserve Chairman Jerome Powell.
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Why Nokia Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 19, 2023
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.